On Jul. 8, 2020 Moderna announced that it had completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate (mRNA-1273) against COVID-19. mRNA-1273 is Modernaﾒs second mRNA vaccine for an infectious disease to complete enrollment of a Phase 2 study, following the Companyﾒs CMV Phase 2 study, which was fully enrolled on Mar. 3, 2020.